Literature DB >> 26463914

The Evolution of the Clinical Use of Osmotic Therapy in the Treatment of Cerebral Edema.

Michael N Diringer1.   

Abstract

For almost a century, it has been known that hypertonic solutions shrink cerebral tissue. Early attempts used hypertonic solutions of ions (sodium, magnesium) and sugars (glucose, dextrose, sucrose), concentrated albumin, and, later, urea. These early attempts were largely abandoned because the effect was short lived and often followed by a period of rebound edema. This was a result, to a great extent, of the osmotic agent either being metabolized or crossing the cell membrane.Renewed interest in osmotic therapy came in the 1960s, with the introduction of intracranial pressure monitoring in head injury and the use of mannitol as an osmotic agent. In the 1990s, use of hypertonic saline was reintroduced as an alternative to address concerns about mannitol. More recently, administration of hypertonic saline has transitioned from boluses to continuous infusions. The rationale for and data supporting the use of continuous infusions are presented.

Entities:  

Keywords:  Cerebral edema; Hypertonic saline; Intracranial hypertension; Mannitol

Mesh:

Substances:

Year:  2016        PMID: 26463914     DOI: 10.1007/978-3-319-18497-5_1

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  3 in total

1.  Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials.

Authors:  Jiajie Gu; Haoping Huang; Yuejun Huang; Haitao Sun; Hongwu Xu
Journal:  Neurosurg Rev       Date:  2018-06-15       Impact factor: 3.042

2.  Hyperosmotic treatment synergistically boost efficiency of cell-permeable peptides.

Authors:  Hu Wang; Ming Zhang; Fanhui Zeng; Changbai Liu
Journal:  Oncotarget       Date:  2016-11-15

3.  Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis.

Authors:  Jiamin Shi; Linhua Tan; Jing Ye; Lei Hu
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.